NOW Thai HAART Study
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00367731|
Recruitment Status : Completed
First Posted : August 23, 2006
Last Update Posted : August 23, 2006
After Initiation of HAART in peoples who living with HIV/AIDS in Thailand by the year 2000, rapidly expanded HAART access of national project has been promoted in 2004. Free ARVs (For CD4<200cell/cu.mm. or in symptomatic HIV with CD4<250 cell/cu.mm. )and CD4 monitoring has been available. The first-line regimen is d4T+3TC+NVP in mainly the first time (Naive) patients. CD4 response ), rate of opportunistic infection, and neurological outcomes were measured. Rate of ARV change, adverse events,treatment failure, TB co-infection rate, percent changing to EFV-based regimen or PI-based regimen were recorded.
Any Adverse Events including, Sever rash, Severe Hepatitis, Lipid abnormalities, Severe Anemia and Other, common AEs will be analysed.
|Condition or disease||Intervention/treatment|
|HIV AIDS Neurological Complications||Drug: Highly Active Antiretroviral Treatment (combination of :NRTI, NNRTI,or PI)|
|Study Type :||Observational|
|Enrollment :||500 participants|
|Observational Model:||Defined Population|
|Observational Model:||Natural History|
|Official Title:||Neurological Outcomes With in THAI National HAART Program.|
|Study Start Date :||January 2005|
|Study Completion Date :||September 2006|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00367731
|Bangkok, Thailand, 10400|
|Principal Investigator:||Subsai Kongsaengdao, M.D.||Rajavithi Hospital|